Search Results
An Update on Lutetium-177 for Prostate Cancer | Thomas Hope, MD & Mark Moyad, MD, MPH | 2021 PCRI
The Story Behind the FDA's Approval of PSMA for Prostate Cancer | Thomas Hope, MD & Mark Moyad, MD
2021: PSMA and Prostate Imaging | Dr. Thomas Hope | 2021 Moyad + Scholz Mid-Year Update | PCRI
Radiation Exposure from Prostate Imaging | Thomas Hope, MD & Mark Moyad, MD | 2021 PCRI Conference
Rising PSA: How Soon Should You Get a Scan? | Thomas Hope, MD & Mark Moyad, MD | 2021 PCRI
RSVP Now for PCRI's 2021 Moyad + Scholz Mid-Year Update | March 27, 2021, 10:30am PDT
New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRI
3 Future Prostate Cancer Treatment Advancements | Mark Scholz, MD & Mark Moyad, MD | 2021 PCRI
Lutetium-177 and Bipolar Androgen Therapy: Future Game Changers In Prostate Cancer | PCRI
PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022
PSMA & Lutetium-177 in 2022 | Eugene Kwon, MD | DIY Combat Manual for Beating Prostate Cancer Part 4
Lutetium-177, Radiation For Urinary Flow, ProstRcision, & Ice For Chemo Side Effect | PCRI #12
